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The diuretic effect of desmethyl-pipazuroyl-guanidine 
(MK-870l in man 
The diuretic properties of desmethyl-pipazuroyl-guanidine (MK) have been investigated in 
man and compared with hydrochlorothiazide (HC). In single-dose studies MK (30 mg.) 
had a slower onset of action and lower peak response than H C. It caused K + retention and 
did not affect Cl output. When administered daily for five days, MK again had a lower peak 
response than HC, but its effect was maintained for a longer period and after five days 
the natriuresis produced by each drug was approximately the same. When MK and HC 
were given together, there was a greater natriuresis and the K loss produced by HC 
was reduced. Both diuretics lowered blood pressure, but MK appeared to be 
less effective than HC. 
Gerhart Hitzenberger, M.D., Hermann Kampffmeyer, M.D., and 
James Conway, M.D., Ph.D. Ann Arbor, Mich. 
Departments of Internal Medicine and Pharmacology, University of Michigan Medical Center 
A new drug, desmethyl-pipazuroyl-gua-
nidine (MK), has shown promise in studies 
in animals1 and in man6 , 9 as a natriuretic 
agent with reduced excretion of potassium. 
The purpose of the present study was to 
assess the diuretic eHect of MK in man 
and compare it with the eHect of hydro-
chlorothiazide (He) ; the two drugs in 
combination were also studied. 
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Our experimental design has been 
divided into three parts: (1) an acute 
study involving the administration of single 
doses of the drugs to normal subjects, (2) 
a six-day study in normal subjects, and (3) 
a seven-day balance study in hypertensive 
patients. 
Short-term study 
Methods. The study was carried out in 
8 healthy young male volunteers who were 
admitted to the hospital for 36 hours. Prior 
to admission, they were given a "no added 
salt diet" and received supplementary 
sodium chloride (3 Gm. per day) with a 
mean sodium intake of 180 mEq. per day. 
After midnight of the day of the experi-
ment, no food or fluid intake was allowed; 
but during the next day, a standard sodium 
intake of 110 mEq. and a fluid intake of 
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200 ml. every 2 hours was given over a 
14 hour period. No coffee, tea, or alcohol 
was given. At 8:00 A.M. the subjects re-
ceived unidentified capsules of MK, He, a 
combination of both, or a placebo. The 
order in which the subjects were given 
the drugs was determined by the Latin 
square method. 
ject remained on the prescribed diet for 
one week. The subjects voided at 8:00 
A.M. and thereafter every 2 hours for 16 
hours and an overnight specimen from 
the sixteenth to twenty-fourth hours. 
Sodium, potassium, chloride, pH, bicar-
bonate, titrable acidity, osmolality, and 
creatinine levels were determined in each 
urine sample. Uric acid output was de-Between each of these studies, the sub-
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Fig. 1. Mean time course of the diuretic action of MK and He alone and in combination as 
compared with placebo. Urine collections were made at two-hourly intervals from 8:00 A .M., 
when the drugs were administered, to midnight. The 24 hour output was then averaged to 
give the mean two-hourly output, indicated by M on the time scale. 
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termined for the whole 24 hour period. A 
single venous blood sample was drawn 
without venous stasis at 8:00 A.M. for 
sodium, potassium, chloride, bicarbon-
ate, osmolality, and creatinine deter-
minations. 
Sodium and potassium were determined 
by flame photometry. Automated colori-
metric methods were used for creatinine, 
chloride, and uric acid analyses. Osmolal 
concentrations were determined by the 
freezing point technique with the use of 
a Fiske osmometer. Titratable acid in urine 
was determined by titrating a small aliquot 
to pH 7.4 with 0.10N base, with a pH 
meter. Carbon dioxide content was mea-
sured on carefully protected urine and 
serum specimens with a Natelson micro-
gasometer. These methods apply to all the 
parts of this report. 
Two dosage levels of the drugs have been 
studied. Four subjects received 10 mg. MK 
(approximately 0.15 mg. per kilogram), 
50 mg. HC, or two placebo capsules. The 
other 4 subjects received the same medica-
tions at double the above doses. 
Results. Fig. 1 illustrates the time course 
and total effect of each drug regimen at 
the lower dosage as compared with 
placebo. In the doses given, MK had a 
slightly slower onset of action and both 
the peak natriuretic response and total 
effect were lower than for He. The com-
bination of the two drugs increased the 
output of sodium in 24 hours from 361 to 
Table I. Mean (+ standard error) output per day 
Drug dose Sodium 
(mg.) (mEq.) 
He 50 360 ± 36.1 
100 364 ± 37.5 
MK 10 271 ± 24.1 
20 324 ± 11.8 
Combination 
He 50 
+ MK 10 408 ± 28.0 
He 100 
+ MK 20 476 ± 20.6 
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407 mEq. Potassium excretion was signif-
icantly increased with HC and significantly 
reduced below control with MK (p 
< 0.05). In combination, the potassium 
excretion was approximately at the control 
level. The titratable acid was significantly 
reduced and HC03 excretion was signif-
icantly increased with MK, but chloride 
excretion was unaffected. 
The osmolal clearance was not markedly 
enhanced with MK (4 m!. per minute 
compared to 3.7 m!. on the placebo day), 
whereas it was increased to 5.25 m!. per 
minute with HC and to 5.38 m!. per minute 
with the combination. The negative free 
water clearance of -260 mI. per two-hour 
period on the placebo day was not signif-
icantly changed by the administration of 
MK (-266 m!.), but it was enhanced by 
HC (-340 m!.), and less pronounced by 
the combination (-281 m!.). The uric acid 
output with MK was 677 ± 97.4 mg. per 
day, while that with HC was 481 ± 36.1 
mg. per day and the control was 558 ± 57.0 
mg. per day. The combination of drugs 
gave an output very similar to HC, 488 ± 
78.1 mg. per day. 
When the higher dose of the drug was 
used, the output of sodium was not 
significantly greater with HC; with MK, 
the output of sodium increased by only 53 
mEq. per 24 hours and this carried over 
to the combination of drugs (Table I). 
The potassium-conserving effect of MK 
was more prominent at the higher dosage 
Potassium Titratable acid 
(mEq.) (mEq.) 
91.0 ± 22.3 20.0 ± 2.4 
102.0 ± 10.7 25.0 ± 4.9 
46.0 ± 8.8 11.0 ± 2.3 
35.3 ± 8.4 10.9 ± 0.8 
75 ± 5.0 20.6 ± 1.6 
52 ± 6.8 10.8 ± 8.7 
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Table II. Mean urinary values (± S.E.) in 8 healthy male volunteers receiving MK-870 
Volume Na 
(ml.) (mEq.) 
Without drug 
(mean of 4 days) 1,122 ± 78.4 191.7 ± 12.2 
1 day MK, 10 mg. 1,373 ± 143.9 257.5 ± 20.7 
2 days MK, 10 mg. 1,378 ± 119.5 231.9 ± 15.3 
3 days MK, 10 mg. 1,286 ± 178.3 138.8 ± 17.1 
4 days MK, 10 mg. 1,326 ± 188.5 165.1 ± 12.1 
5 days MK, 20 mg. 1,215 ± 102.3 165.1 ± 19.8 
6 days MK, 20 mg. 1,366 ± 194.8 178.0 ± 16.6 
and this was maintained when the drugs 
were given together. 
Six day study in normal subjects 
Methods. This study was performed on 
an outpatient basis in 8 male subjects. 
Twenty-four hour urine collections were 
taken and measured for 4 days prior to 
treatment and for 6 days during treatment 
with MK. The volunteers ate a normal 
diet; only the intake of foods with high 
purine content was prohibited (liver, kid-
ney). Tea and coffee were permitted, but 
in those who did it was mandatory that 
they take either two cups of coffee or tea 
per day. The subjects received MK, 5 
mg. twice a day for 4 days, and then MK, 
10 mg. twice a day for the remaining 2 
days. A blood sample was drawn on three 
occasions before treatment and after the 
first, second, and fifth day of treatment 
for determination of sodium, potassium, 
chloride, HC03 , creatinine, uric acid, and 
hematocrit. In the urine, determinations of 
sodium, potassium, chloride, creatinine, 
and uric acid were made. 
Three of these subjects undertook a 
further trial with MK at 30 mg. per day 
in divided dosage for 3 days to determine 
the blood levels of the drug. \) Venous blood 
samples were drawn, four after the first 
10 mg. dose and then daily for 3 days. 
~Determination of blood levels were performed for 
us by Merck Sharp & Dohme through the courtesy of 
Dr. P. W. Boyles. 
Uric acid 
Creatinine clearance 
K Cl clearance (L./24 
(mEq.) (mEq.) (L./24 hours) hours) 
57.9 ± 7.1 148.5 ± 19.7 133.75 ± 5.67 12.08 ± 0.59 
43.1 ± 2.4 192.9 ± 21.1 136.75 ± 14.34 12.25 ± 1.71 
46.6 ± 5.1 211.3 ± 17.0 133.57 ± 10.77 12.42 ± 1.03 
43.4 ± 4.8 172.9 ± 20.5 117.51 ± 10.17 13.29 ± 3.23 
62.7 ± 6.9 172.6±16.1 
50.3 ± 4.2 160.0 ± 21.1 
56.1 ± 3.8 154.1 ± 15.1 134.2 ± 6.12 10.83 ± 1.49 
Results. The results of this study are 
presented in Table II. There was a modest 
increase in sodium output; the potassium 
excretion showed a slight drop for 3 days 
and returned to control levels on the fourth 
day. The increased dosage at this point 
had a small but temporary effect on the 
potassium output. The average uric acid 
level in the serum was 6.13 mg. per cent 
prior to the treatment and 6.04 mg. per 
cent after 5 days of treatment. Uric acid 
clearance did not change. There was a 
small drop in serum HC03 , with no sub-
stantial change in serum sodium, potas-
sium" or chloride. There was no significant 
change in serum creatinine Or in its excre-
tion in the urine. A transient increase of 
the mean hematocrit level occurred after 
2 days of treatment from 46 to 48 per cent. 
The blood levels of MK increased from 
undectable levels to 0.02 mg. per milliliter 
within 4 hours of the administration of the 
first dose and then varied between 0.02 
to 0.04 mg. per milliliter for the succeeding 
3 days without evidence of progressive in-
crease. 
Balance study in hypertensive patients 
Methods. These studies were carried out 
in the Clinical Research Unit of the Uni-
versity of Michigan Hospital on 15 un-
treated hypertensive patients. These pa-
tients were recruited from the outpatient 
clinic, and their disease states were of 
moderate severity with a mean blood pres-
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Table III. Mean diuretic response in five subjects to MK (30 mg. per day) 
administered for 5 days followed by hydrochlorothiazide (100 mg. per day) for 2 days 
Serum level Creatinine 
Daily urinary output Na K Cl clearance Body 
weight Volume I Na I K I Cl (mEq./ (mEq./ (mEq./ (L./24 
Drug Day (Kg.) (ml.) (mEq.) (mEq.) (mEq.) L.) L.) L.) hours) 
Control" 68.7 1,114.0 28.4 50.0 36.0 143.8 4.37 105.4 137.6 
5.3t 22l.8t 6.2t 4.lt 8.5t l.4t 0.16t 0.9t 12.6t 
MK 1 68.3 1,647.0 162.8 43.8 79.0 142.6 5.15 106.8 136.4 
5.2 214.0 19.8 7.5 6.8 l.8 0.22 1.1 17.0 
2 67.7 1.703.0 166.0 53.2 130.0 142.2 4.88 107.2 119.2 
5.2 232.4 15.7 6.5 5.5 1.1 0.31 l.0 9.6 
3 67.5 1,787.0 149.9 64.2 138.0 141.5 4.79 106.2 127.0 
5.0 21l.6 9.4 6.8 8.2 1.0 0.20 0.9 17.4 
4 67.6 1,439.0 112.2 66.5 107.0 142.2 5.21 106.4 119.2 
5.4 133.9 6.4 12.5 6.9 0.5 0.15 l.2 7.2 
5 67.3 1,825.0 107.0 67.3 130.0 141.2 5.13 106.8 123.2 
5.5 114.5 4.3 20.1 l.0 0.9 0 .. 32 1.1 18.7 
HC 1 66.9 1,886.0 132.8 134.2 182.0 141.0 5.02 103.0 101.4 
5.4 327.2 2l.2 3.4 32.4 1.3 0.30 1.6 33.0 
2 66.7 1,322.0 78.2 112.8 129.0 140.4 3.96 101.0 118.6 
5.4 157.6 19.1 5.2 12.7 0.2 0.17 1.5 13.1 
-o-Control represents the mean of the values for 2 days preceding the administration of the diuretic. 
fStandard error. 
sure of 169/107 mm. Hg. None had papill-
edema or hemorrhages and exudates. The 
subjects had normal renal function and 
no evidence of cardiac failure; clinical 
edema was not evident in any subject. 
They were given a 44 mEq. sodium diet 
with supplementation to 94.8 mEq. per 
day. There was no fluid restriction. Body 
weight was recorded daily and a de-
termination was made of serum sodium, 
potassium, chloride, bicarbonate, uric acid, 
and creatinine. The urine was collected 
every 24 hours for determination of vohune, 
sodium, potassium, chloride, creatinine, and 
uric acid. 
After a control period of 4 days, the 
15 subjects were divided into 3 groups of 5 
each. Group A was treated with MK, 30 
mg. per day for 5 days, which was then 
discontinued and immediately changed to 
He, 100 mg. per day for 2 days. In Group 
B, the effect of He, 100 mg. per day, was 
studied. After 5 days MK, 30 mg. per day 
was added. In Group e, 50 mg. per day 
of He was given, and after 5 days 30 mg. 
per day of MK was added. 
Results. 
Group A. The results of Group A are 
shown in Table III. A rise in urine volume 
was observed and maintained for the 5 
days of treatment with MK. The body 
weight showed a moderate but steady 
decrease of 1.4 Kg. and decreased further 
with the addition of He. The sodium out-
put increased with MK, being greatest on 
the :6rst day of the drug administration 
(162.8 mEq. per day) and falling to 107.0 
mEq. per day in 5 days. The change to 
He treatment at this point increased the 
output to 132.8 mEq. per day, demonstrat-
ing He to be a more potent diuretic in 
the dosage used. 
The creatinine clearance was reduced by 
14.4 L. per day with administration of MK 
and was further reduced with He. A 
76 H itzenberger, KampfJmeyer, and Conway Clinical Pharmacology 
and Therapeutics 
Table IV. Mean diuretic response in 5 subjects to hydrochlorothiazide (100 mg. 
per day) administered for 5 days followed by hydrochlorothiazide (100 mg. per 
day) and MK (30 mg. per day) combined 
Serum level Creatinine 
Body Daily urinary output Na K Cl clearance 
weight Volume I Na I K I Cl (mEq./ (mEq./ (mEq./ (L./24 
Drug Day (Kg.) (ml.) (mEq.) (mEq.) (mEq.) L.) L.) L.) hours) 
Control" 76.4 1,561.1 84.3 63.8 90.6 141.2 4.15 106.4 134.2 
3.2t 230.5t 13.8t 5.3t 9.4t 0.6t 0.19t 1.1t 5.2t 
HC 1 75.1 2,875.0 267.8 114.4 289.4 139.8 3.72 101.8 151.8 
3.2 371.0 19.1 15.8 8.5 0.8 0.08 1.1 16.6 
2 74.7 2,013.0 146.0 86.8 167.2 140.0 4.01 99.2 120.6 
3.2 187.6 4.1 8.4 5.8 0.7 0.08 1.2 11.9 
3 74.3 1,828.0 97.2 98.2 119.4 140.8 3.65 99.2 127.0 
3.3 255.9 2.1 14.5 3.8 0.9 0.11 1.0 7.7 
4 74.1 1,774.1 81.6 100.2 97.8 140.0 3.57 99.4 126.6 
3.2 296.4 7.9 13.1 0.6 0.9 0.60 1.0 7.9 
5 73.9 1,626.0 70.0 94.8 83.8 138.2 3.35 98.4 124.4 
3.2 302.5 9.2 12.0 5.2 0.3 0.06 1.1 9.2 
HC 1 73.8 1,937.4 177.8 35.2 93.8 1.38.2 3.89 99.8 110.6 
+ MK 3.2 210.5 15.9 8.8 7.6 0.5 0.12 0.8 7.4 
2 73.6 1,885.0 160.2 34.0 102.2 137.5 4.38 102.2 121.0 
3.2 210.5 11.3 7.1 12.4 1.0 0.17 1.1 6.0 
°Control represents the mean of the values for 2 days preceding the administration of the diuretic. 
fStandard error. 
small rise in uric acid excretion was found 
with MK. This averaged 661.28 ± 112.6 mg. 
per day, whereas the mean 24 hour excre-
tion was 537.8 ± 64.3 mg. per day prior to 
treatment. This difference was significant 
at the 5 per cent level. The mean serum 
uric acid value was, however, not altered. 
The serum bicarbonate level fell from 
28.7 ± 2.0 to 23.3 ± 9.5 mEq., reflecting a 
slight metabolic acidosis; this was re-
versed with He rising to 29.6 ± 3,4 mEq. 
per liter. The mean blood pressure before 
therapy was 167/106 mm. Hg; it fell to 
152/103 mm. Hg with MK and then to 
135/92 mm. Hg with He. 
Results. 
Group B. The results of Group Bare 
shown in Table IV. When compared with 
the response to MK, the sodium excretion 
was initially much greater with He. On 
the first day of treatment it reached a peak 
of 267.8 mEq. per day but it fell rapidly 
to 70 mEq. per day in 5 days; it rose 
when MK was added. Simultaneously, 
there was a fall in serum sodium concen-
tration from 141.2 to 138.2 mEq. with He 
and to 137.5 with the combination. The 
total negative sodium balance at this point 
was calculated to be 302.7 mEq. The 
potassium excretion increased markedly 
with He and was sustained over the 5 
day period of treatment, with a fall in the 
serum value from 4.1 ± 0.35 to 3.35 ± 0.06. 
With the addition of MK, potassium excre-
tion was greatly reduced and the serum 
value returned to 4.38 ± 0.17 in 2 days. 
The mean blood pressure in this section 
of the study fell from 172/110 to 150/94 
with He and to 134/90 mm. Hg with the 
combination treatment of the two diuretics. 
While He was initially more potent 
than MK, its action was not sustained. 
When the 5 day periods during which 
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Table V. Mean diuretic response in five hypertensive subjects to hydrochloro-
thiazide (50 mg. per day) followed by hydrochlorothiazide (50 mg. per day) and 
MK (30 mg. per day) combined 
Serum level Creatinine 
Body Daily urinary output Na K Cl clearance 
weight Volume I Na I K I cl (mEq./ (mEq./ (mEq./ (L./24 
Drug Day (Kg.) (ml.) (mEq.) (mEq.) (mEq.) L.) L.) L.) hours) 
82.8 1,574 88.6 67.4 95.2 142.6 4.52 102.4 162.0 
3.15" 93.70" 6.64" 3.95" 14.56" 1.87" 0.28" 1.10" 13.36" 
HC 1 82.0 2,546 240.0 117.4 
2.97 259.60 17.06 9.59 
2 81.3 1,885 124.3 113.7 
2.86 463.0 22.11 20.96 
3 81.0 1,391 85.4 115.0 
2.78 133.36 3.91 10.7 
4 80.8 1,546 81.8 124.0 
2.90 191.50 5.09 17.5 
5 79.3 1,250 57.9 95.9 
2.92 169.93 5.69 1.66 
HC 1 81.3 1,721 230.8 27.5 
+ MK 3.12 247.57 6.21 5.64 
2 80.7 1,560 181 19.1 
3.08 198.0 10.24 
°Standard error. 
each drug was given alone are compared, 
the total negative sodium balance with 
MK was 222.0 mEq. and 188.0 mEq. with 
He. Since the patterns of response to MK 
and He were so different, it seemed de-
sirable to determine whether this was a 
reflection of different pharmacologic prop-
erties of the two drugs or whether this 
was the result of differences in potency. 
A further trial was therefore, made with 
He at lower dosage. 
Results 
Group C. With reduced dosage of He 
(50 mg. per day), the peak response on 
the Rrst day (240.0 mEq.) was a little 
lower than that achieved with the higher 
dose (Table V). On succeeding days, the 
response fell off sharply and on the third 
day was below the intake level (85.4 mEq. 
3.27 
276.8 143.2 3.96 98.4 156.6 
23 .. '36 3.81 0.21 1.89 17.52 
152.0 140.0 3.85 99.4 133.3 
26.12 0.63 0.21 0.89 13.10 
112.7 142.2 3.9 99.4 133.8 
4.63 1.31 0.25 1.67 8.10 
112.4 141.0 3.5 98.3 174.0 
9.27 2.50 0.1 1.73 21.67 
84.3 141.0 3.77 98.6 144.1 
6.69 0.61 0.16 1.30 6.60 
111.5 140.5 3.85 99.0 147.1 
3.78 0.56 0.2 1.64 12.34 
124.8 137.5 4.25 100.2 132.6 
5.45 0.75 0.14 1.46 18.47 
per day). On the Rfth day, the sodium 
balance was markedly positive; at this 
point the addition of MK (30 mg. per day) 
greatly increased sodium output. 
Discussion 
The sodium excretion with MK admin-
istration, in the doses used, when given as 
a single dose or for a single day never 
reached the peak values achieved by He. 
However, when the drug was given on 
successive days, the effectiveness of MK 
was better sustained; and over a 5 day 
period, the negative balance achieved was 
approXimately the same as that with He 
at the conventional maximal dosage of 100 
mg. per day. There are several possible 
explanations for this. If there were a given 
quantity of sodium which could be readily 
removed, the weaker drug might continue 
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to be effective until this was accomplished. 
This is not supported by the observations 
with He, in which reduction in dosage did 
not prolong response but shortened it. 
Tissue levels of MK might increase on 
successive days. Others have found some 
evidence in 3 subjects for increasing blood 
concentration of MK, which could not be 
confirmed by us. MK may possess a dual 
action-a direct natriuretic effect and an-
other and different one sustaining the na-
triuretic effect. This possibility is of in-
terest since a response sustained over many 
days has also been observed with spirono-
lactone. 7 Thus, the continued availability 
of both potassium and chloride ions at the 
tubular exchange sites may assist the con-
tinued sodium output. Another possibility 
for the prolonged natriuretic effect is the 
production of a mild acidosis. This along 
with potassium retention will favor the 
movement of sodium from muscle cells 
into the extracellular fluid and make it 
available for excretion. 3 It would be ex-
pected, therefore, that MK would result 
in an extraction of sodium from both the 
cellular and extracellular compartment, 
whereas He would tend to bring about a 
loss of sodium from extracellular fluid with 
the possible accumulation of sodium in 
muscle cells. 
He and MK are for practical purposes, 
therefore, approximately equal in potency 
and in combination produce additive di-
uresis. Since it has been our feeling that 
the small size of the negative sodium bal-
ance achieved by He limits its antihyper-
tensive action,2 this combination may be of 
value in the treatment of hypertension. 
Furthermore, the added diuretic response 
may well be achieved without hypokalemia 
or alkalosis since the potassium retention 
achieved by MK can balance the loss 
from He. 
The potassium-saving effect was to be 
expected, from evidence in other stud-
ies.1 , 6, 8, 9 This effect is similar to that of 
triamterene5 ; but there is a less pronounced 
bicarbonate excretion and, therefore, a 
metabolic acidosis seems to occur more 
readily with MK than with triamterene. 
Thus, the effect of MK counteracting the 
metabolic hypokalemic alkalosis produced 
by He seems to be more effective than that 
of triamterene. Since the single-dose stud-
ies showed that potassium output fell be-
low control and in the longer studies serum 
potassium rose, it is misleading to use the 
term "potassium-sparing." Actually, there 
is potassium retention and hyperkalemia 
could occur. The accumulation of potas-
sium in the doses used in this study ap-
pears to be limited to 2 to 3 days, how-
ever, and even when the drug is given on 
successive days, the output returns to con-
trol levels. 
The decrease of the creatinine clearance 
which takes place with MK is similar to 
that with He. This is not surprising since 
reduced renal blood flow and glomerular 
filtration rate have been reported with 
both ethacrynic acid and hydrochlorothia-
zide.4 This appears to be a response to 
the contraction in extracellular fluid volume 
and not the result of a specific effect of 
these drugs, since it is evident only after 
a considerable loss of sodium. 
The effect of MK on uric acid excretion 
requires further study; it seems that a 
mild uricosuric action may have occurred 
after single doses as well as after a five 
day treatment. This could not, however, 
be demonstrated on a daily dose of 10 to 
20 mg, MK over several days in outpa-
tients. 
At first glance MK seemed to be a mild 
diuretic with the virtue of conserving po-
tassium. However, when given repeatedly 
over several days, its effect was better 
maintained than that of He. The negative 
sodium balance achieved is the same with 
both agents. When combined, a substan-
tial natriuretic effect could be induced 
without hypokalemia. MK appeared to 
possess antihypertensive properties, as do 
other diuretic agents, and the combination 
with He appeared to increase it. Since the 
effect of bed rest in these studies compli-
cates the estimation of the antihyperten-
sive effect, a different experimental design 
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will be required to quantitate the antihy-
pertensive action. 
Summary 
1lle diuretic action of desmethyl-pipa-
zuroyl-guanidine (MK) has been investi-
gated in 31 subjects and a comparison 
made with hydrochlorothiazide (He). The 
drugs were also used in combination. 
The results indicate that 10 mg. of MK 
was less potent a diuretic than 50 mg. of 
He. These were approximately the max-
imally effective oral doses of these drugs 
in normal subjects. Both drugs had the 
same duration of action when given as a 
single dose. 1lle output of potassium fell 
below control levels with MK, while bi-
carbonate excretion increased. 
On continued therapy, MK (30 mg. per 
day) caused a smaller peak response than 
He; but the natriuretic effect was sustained 
for at least 5 days as opposed to 3 days 
for He (100 mg. per day), so that the 
negative sodium balance produced in 5 
days by both was approximately equal. MK 
reduced the excretion of titratable acid and 
increased the excretion of bicarbonate, thus 
giving rise to a slight metabolic acidosis 
in contrast to the metabolic alkalosis pro-
duced by He. The decrease in potassium 
excretion produced by this drug was limit-
ed to the first 2 to 3 days of therapy, after 
which it returned to the control level. 
MK produced an added diuretic response 
to continued thiazide therapy and reversed 
the potassium loss and the slight alkalosis 
achieved with this drug. It also appeared 
to have an antihypertensive effect. 
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